Open-label cross-over study to evaluate the amount of residual inhaled corticosteroid (hydrofluoroalkane-134a beclomethasone dipropionate (HFA-BDP) and fluticasone propionate dry powder inhaler (FP-DPI)) in the mouths of elderly asthmatic patients after each inhalation

Open-label cross-over study to evaluate the amount of residual inhaled corticosteroid (hydrofluoroalkane-134a beclomethasone dipropionate (HFA-BDP) and fluticasone propionate dry powder inhaler (FP-DPI)) in the mouths of elderly asthmatic patients after each inhalation - The evaluation of the amount of residual inhaled corticosteroid (HFA-BDP and FP-DPI) in the mouths of elderly asthmatic patients after each inhalation.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000001323

Enrollment

Registered

2008-08-25

Start date

2008-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Asthma

Interventions

After evaluating the outcome of HFA-BDP administration, switch to FP-DPI in an equivalent dose. 4 weeks after the switch evaluate its outcome in same way as HFA-BDP. After evaluating the outcome of F

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Asthmatic patients who use HFA-BDP or FP-DPI for more than 3 months with good adhererance. 2. Well-controlled asthma, 3. Non-smoker or ex-smoker more than 1 year after smoking cessation

Exclusion criteria

Exclusion criteria: 1)any hypersensitivity history for steroids, 2)under treatment with oral steroids, 3)under desensitization or non-specific therapy which is newly initiated within 6 months before this study, 4)other coexisting chronic respiratory diseases except for chronic obstructive pulmonary disease (COPD), 5)severe hepatic or renal disease, heart failure, hematologic diseases, or other severe co-morbid disease, 6)under treatment for chronic respiratory infectious diseases, 7)expectation of poor drug compliance, 8)Inappropriate patients from the doctor's viewpoint

Design outcomes

Primary

Measure	Time frame
the amount of residual inhaled corticosteroids in gargled fluids, peak inspiratory flow,	—

Secondary

Measure	Time frame
pharyngeal culture for candida, and patient questionnaires	—

Countries

Japan

Contacts

Public ContactHiroyuki Ohbayashi

JA Gifu Kouseiren Tohno-Kousei Hospital Dept. of Allergy and Respiratory Medicine

ohbayasi@nn.iij4u.or.jp0572-68-4111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026